Metraipolis › archive › dc_377931334eab
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes — Europe PMC PMID:42311743
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42311743
- DOI
- 10.7759/cureus.108999
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T16:01:41.028Z
- SHA-256 of the archived text
eef112bdbf9fe8b2307bb02e68d1c53a74214fbaecc0bacf54c79f207b74b4c6- Stable URL of this page
https://metraipolis.com/documento/dc_377931334eab
How to cite
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes — Europe PMC PMID:42311743 — Europe PMC (en), https://europepmc.org/article/MED/42311743 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_377931334eab (Metraipolis archive dc_377931334eab, sha256 eef112bdbf9fe8b2307bb02e68d1c53a74214fbaecc0bacf54c79f207b74b4c6)
BibTeX
@misc{dc377931334eab,
title = {Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes — Europe PMC PMID:42311743},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42311743},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_377931334eab; sha256 eef112bdbf9fe8b2307bb02e68d1c53a74214fbaecc0bacf54c79f207b74b4c6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42311743. Agents can read the archived copy with the MCP tool read_document.